Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ASH 2023
Pharma
An Imbruvica combo regimen could have a new future in MCL
AbbVie is making the case for its Johnson & Johnson-partnered BTK inhibitor Imbruvica to stage a comeback in mantle cell lymphoma.
Fraiser Kansteiner
Dec 12, 2023 12:33pm
ASH: J&J, Sanofi square off in newly diagnosed multiple myeloma
Dec 12, 2023 12:00pm
ASH: Abecma's overall survival data show why FDA called adcomm
Dec 11, 2023 7:30pm
ASH: Roche offers glimpse at Columvi-Polivy combo in DLBCL
Dec 11, 2023 7:00am
ASH: Study digs into FDA adverse event record of BCMA therapies
Dec 11, 2023 2:46am
ASH: Adcetris, Opdivo boost hopes for another ADC, PD-1 combo
Dec 10, 2023 7:30pm
